The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.
Name: BGB-3111Description: BGB-3111 will be administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)Type: Drug
Name: obinutuzumabDescription: Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks. 1 cycle = 28 days.Type: Drug
Arm A Arm B
Description: Safety and TolerabilityMeasure: Incidence, timing, severity of treatment-emergent adverse events (TEAEs) Time: up to 3 years
There is one SNP
Requires ongoing treatment with a strong Cytochrome P4503A (CYP3A) inhibitor or inducer. --- P4503A ---